Abstract
The impact of covalent binding on PROTAC-Mediated degradation of BTK was investigated through the preparation of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib. It was determined that a covalent binding PROTAC inhibited BTK degradation despite evidence of target engagement, while BTK degradation was observed with a reversible binding PROTAC. These observations were consistently found when PROTACs that were able to recruit either IAP or cereblon E3 ligases were employed. Proteomics analysis determined that the use of a covalently bound PROTAC did not result in the degradation of covalently bound targets, while degradation was observed for some reversibly bound targets. This observation highlights the importance of catalysis for successful PROTAC-Mediated degradation and highlights a potential caveat for the use of covalent target binders in PROTAC design.
Original language | English |
---|---|
Pages (from-to) | 342-347 |
Number of pages | 6 |
Journal | ACS Chemical Biology |
Volume | 14 |
Issue number | 3 |
Early online date | 26 Feb 2019 |
DOIs | |
Publication status | Published - 15 Mar 2019 |
Keywords
- PROTAC
- drug discovery
- cellular degradation
- protein degradation
- E3 ubiquitin-protein ligases
- tyrosine kinase